Intrathecal or intraventricular colistin: A review

Infezioni in Medicina

Volumn 24, Issue 1, 2016, Pages 3-11

  Bargiacchi, Olivia ^a   De Rosa, Francesco Giuseppe ^b  

^a MAGGIORE DELLA CARITÀ HOSPITAL   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Central nervous system infection; Colistin; Intrathecal; Intraventricular; Pharmacokinetics

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AZTREONAM; CEFOTAXIME; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; FOSFOMYCIN; GENTAMICIN; IMIPENEM; LINEZOLID; MEROPENEM; RIFAMPICIN; SULTAMICILLIN; TIGECYCLINE; TOBRAMYCIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ACINETOBACTER BAUMANNII; ANTIBIOTIC SENSITIVITY; BLOOD BRAIN BARRIER; BLOOD LEVEL; BRAIN VENTRICULITIS; CATHETER; CENTRAL NERVOUS SYSTEM INFECTION; COAGULASE NEGATIVE STAPHYLOCOCCUS; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DIFFUSION; DRUG HALF LIFE; DRUG PENETRATION; EXTERNAL CATHETER DERIVATION; GRAM NEGATIVE BACTERIUM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIQUORRHEA; MENINGITIS; MULTIDRUG RESISTANCE; PLASMA CONCENTRATION-TIME CURVE; PSEUDOMONAS AERUGINOSA; REVIEW; TREATMENT DURATION; ACINETOBACTER INFECTIONS; ADVERSE EFFECTS; CENTRAL NERVOUS SYSTEM INFECTIONS; CEREBROSPINAL FLUID SHUNTING; COMPLICATION; DRUG EFFECTS; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; INTRASPINAL DRUG ADMINISTRATION; MICROBIOLOGY; PROCEDURES; TREATMENT OUTCOME;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; CENTRAL NERVOUS SYSTEM INFECTIONS; CEREBROSPINAL FLUID SHUNTS; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; INJECTIONS, INTRAVENTRICULAR; INJECTIONS, SPINAL; TREATMENT OUTCOME;

EID: 84962708946     PISSN: 11249390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. Laxmi S., Tunkel A.R. Healthcare-associated bacterial meningitis. Curr. Infect. Dis. Rep. 13, 367-373, 2011.
2. Lozier A.P., Sciacca R.R., Romagnoli M.F., Connolly E.S. Jr. Ventriculostomy-related infections: a critical review of the literature. Neurosurgery 62, 688-700, 2008.
3. Kim B.N., Peleg A.Y., Lodise T.P., et al., Management of meningitis due to antibiotic-resistant Acinetobacter species. Lancet Infect. Dis. 9, 245-255, 2009.
4. Kim J.H., Desai N.S., Ricci J. et al. Factors contributing to ventriculostomy infection. World Neurosurg. 77, 135-140, 2012.
5. Gutiérrez-González R., Boto G.R., Pérez-Zamarrón A. Cerebrospinal fluid diversion devices and infection. A comprehensive review. Eur. J. Clin. Microbiol. Infect. Dis. 31, 889-897, 2012.
6. Ece G., Samlioglu P., Atalay S., Kose S. Evaluation of the in vitro colistin susceptibility of Pseudomonas aeruginosa and Acinetobacter baumannii strains at a tertiary care centre in Western Turkey. Infez. Med. 1, 36-40, 2014.
7. Tascini C., Menichetti F., Stefanelli A., Loni C., Lambelet P. Clinical efficacy of intravenous colistin therapy in combination with ceftazidime in severe MDR P. aeruginosa systemic infections in two haematological patients. Infez. Med. 1, 41-44, 2006.
8. Bassetti M., Righi E., Esposito S., Petrosillo N., Nicolini L. Drug treatment for multidrug-resistant Acinetobacter baumannii infections. Future Microbiology. 3, 6, 649-660, 2008.
9. Esposito S., Esposito I., Leone S. Considerations of antibiotic therapy duration in community- and hospital- acquired bacterial infections. J. Antimicrob. Chemother. 67, 11, 2570-2575, 2012
10. Nau R., Sörgel F., Eiffert H. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin. Microbiol. Rev. 23, 858-883, 2010.
11. Jiménez-Mejías M.E., Pichardo-Guerrero C., Márquez-Rivas F.J., Martín-Lozano D., Prados T., Pachón J. Cerebrospinal fluid penetration and pharmacokinetic/ pharmacodynamic parameters of intravenously administered colistin in a case of multidrugresistant Acinetobacter baumannii meningitis. Eur. J. Clin. Microbiol. Infect. Dis. 21, 212-214, 2002.
12. Everett E.D., Strausbaugh L.J. Antimicrobial agents and the central nervous system. Neurosurgery. 6, 691-714, 1980.
13. Plachouras D., Karvanen M., Friberg L.E. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gramnegative bacteria. Antimicrob. Agents Chemother. 53, 3430-3436, 2009.
14. Bargiacchi O., Rossati A., Car P., et al. Intrathecal/ intraventricular colistin in external ventricular devicerelated infections by multi-drug resistant Gram negative bacteria: case reports and review. Infection. 42, 801-809, 2014.
15. Jiménez-Mejías M.E., Becerril B., Márquez-Rivas F.J., Pichardo C., Cuberos L., Pachón J. Successful treatment of multidrug-resistant Acinetobacter baumannii meningitis with intravenous colistin sulfomethate sodium. Eur. J. Clin. Microbiol. Infect. Dis. 19, 970-971, 2000.
16. Markantonis S.L., Markou N., Fousteri M., et al. Penetration of colistin into cerebrospinal fluid. Antimicrob. Agents Chemother. 53, 4907-4910, 2009.
17. Antachopoulos C., Karvanen M., Iosifidis E., et al. Serum and cerebrospinal fluid levels of colistin in pediatric patients. Antimicrob. Agents Chemother. 54, 3985-3987, 2010.
18. Imberti R., Cusato M., Accetta G., et al. Pharmacokinetics of colistin in cerebrospinal fluid after intraventricular administration of colistin methanesulfonate. Antimicrob. Agents Chemother. 56, 4416-4421, 2012.
19. Tunkel A.R., Hartman B.J., Kaplan S.L., et al. Practice guidelines for the management of bacterial meningitis. Clin. Infect. Dis. 39, 1267-1284, 2004.
20. Ziaka M., Markantonis S.L., Fousteri M., et al. Combined intravenous and intraventricular administration of colistin methanesulfonate in critically ill patients with central nervous system infection. Antimicrob. Agents Chemother. 57, 1938-1940, 2013.
21. Fotakopoulos G., Makris D., Chatzi M., Tsimitrea E., Zakynthinos E., Fountas K. Outcomes in meningitis/ ventriculitis treated with intravenous or intraventricular plus intravenous colistin. Acta Neurochir. (Wien). 158: 603-610, 2016.
22. Shofty B., Neuberger A., Naffaa M.E., et al. Intrathecal or intraventricular therapy for post-neurosurgical Gram-negative meningitis: matched cohort study. Clin. Microbiol. Infect. 22, 66-70, 2016.
23. De Bonis P., Lofrese G., Scoppettuolo G., et al. Intraventricular versus intravenous colistin for the treatment of extensively drug resistant Acinetobacter baumannii meningitis. Eur. J. Neurol. 23, 68-75, 2016.
24. Price D.J., Sleigh J.D. Klebsiella meningitis-report of nine cases. J. Neurol. Neurosurg. Psychiatry. 35, 903-908, 1972.
25. Kaplan S.L., Patrick C.C. Cefotaxime and aminoglycoside treatment of meningitis caused by gram-negative enteric organisms. Pediatr. Infect. Dis. J. 9, 810-814, 1990.
26. Fernandez-Viladrich P., Corbella X., Corral L., Tubau F., Mateu A. Successful treatment of ventriculitis due to carbapenem-resistant Acinetobacter baumannii with intraventricular colistin sulfomethate sodium. Clin. Infect. Dis. 28(4), 916-917, 1999.
27. Vasen W., Desmery P., Ilutovich S., Di Martino A., Intrathecal use of colistin. J. Clin. Microbiol. 38, 3523, 2000.
28. Benifla M., Zucker G., Cohen A., Alkan M. Successful treatment of Acinetobacter meningitis with intrathecal polymyxin E. J. Antimicrob. Chemother. 54, 290-292, 2004.
29. Quinn A.L., Parada J.P., Belmares J., O’Keefe J.P. Intrathecal colistin and sterilization of resistant Pseudomonas aeruginosa shunt infection. Ann. Pharmacother. 39, 949-952, 2005.
30. Suárez Fernández C., Fernández-Viladrich P., Tubau F., Corral L., Mateu A. Intrathecal colistin treatment of central nervous system infections due to multiresistant Acinetobacter baumannii. In Program and Abstracts of 15th European Congress of Clinical Microbiology and Infectious Diseases Copenhagen, Denmark, April 2-5, 2005, Abstract number: 1134_02_277.
31. Gump W.C., Walsh J.W. Intrathecal colistin for treatment of highly resistant Pseudomonas ventriculitis. Case report and review of the literature. J. Neurosurg. 102, 915, 2005.
32. Kasiakou S.K., Rafailidis P.I., Liaropoulos K., Falagas M.E. Cure of post-traumatic recurrent multiresistant Gram-negative rod meningitis with intraventricular colistin. J. Infect. 50, 348-352, 2005.
33. Bukhary Z., Mahmood W., Al-Khani A., Al-Abdely H.M. Treatment of nosocomial meningitis due to a multidrug resistant Acinetobacter baumannii with intraventricular colistin. Saudi Med. J. 26(4), 656-658, 2005.
34. Sueke H., Marsh H., Dhital A., Using intrathecal colistin for multidrug resistant shunt infection. Br. J. Neurosurg. 19, 51-52, 2005.
35. Berlana D., Llop J.M., Fort E., Badia M.B., Jódar R. Use of colistin in the treatment of multiple-drug-resistant gram-negative infections. Am. J. Health Syst. Pharm. 62, 39-47, 2005.
36. Charra Charra B., Hachimi A., Benslama A., Motaouakkil S. Intrathecal use of colistin. Ann. Fr. Anesth. Reanim. 25, 215, 2006.
37. Karakitsos D., Paramythiotou E., Samonis G., Karabinis A. Is intraventricular colistin an effective and safe treatment for post-surgical ventriculitis in the intensive care unit? Acta Anaesthesiol. Scand. 50, 1309-1310, 2006.
38. Yagmur R., Esen F. Intrathecal colistin for treatment of Pseudomonas aeruginosa ventriculitis: report of a case with successful outcome. Crit. Care. 10, 428, 2006.
39. Ng J., Gosbell I.B., Kelly J.A., Boyle M.J., Ferguson J.K. Cure of multiresistant Acinetobacter baumannii central nervous system infections with intraventricular or intrathecal colistin: case series and literature review. J. Antimicrob. Chemother. 58, 1078-1081, 2006.
40. Al Shirawi N., Memish Z.A., Cherfan A., Al Shimemeri A. Post-neurosurgical meningitis due to multidrug- resistant Acinetobacter baumanii treated with intrathecal colistin: case report and review of the literature. J. Chemother. 18, 554-558, 2006.
41. Motaouakkil S., Charra B., Hachimi A., et al. Colistin and rifampin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii. J. Infect. 53, 274-278, 2006.
42. Schina M., Spyridi E., Daoudakis M., Mertzanos E., Korfias S. Successful treatment of multidrug-resistant Pseudomonas aeruginosa meningitis with intravenous and intrathecal colistin. Int. J. Infect. Dis. 10, 178-179, 2006.
43. Metan G., Alp E., Aygen B., Sumerkan B., Acinetobacter baumannii meningitis in post-neurosurgical patients: clinical outcome and impact of carbapenem resistance. J. Antimicrob. Chemother. 60, 197-199, 2007.
44. Enfanto C.M., Shin S. Treatment with Intrathecal Colistin of a Resistant Extended-Spectrum beta-Lactamase- Producing Klebsiella pneumoniae in the Cerebrospinal Fluid. Infect. Dis. Clin. Pract. 15, 274-277, 2007.
45. Ho Y.H., Wang L.S., Chao H.J., Chang K.C., Su C.F. Successful treatment of meningitis caused by multidrug- resistant Acinetobacter baumannii with intravenous and intrathecal colistin. J. Microbiol. Immunol. Infect. 40, 537-540, 2007.
46. Paramythiotou E., Karakitsos D., Aggelopoulou H., Sioutos P., Samonis G., Karabinis A. Post-surgical meningitis due to multiresistant Acinetobacter baumannii. Effective treatment with intravenous and/ or intraventricular colistin and therapeutic dilemmas. Med. Mal. Infect. 37, 124-125, 2007.
47. Lee C.H., Tang Y.F., Su L.H., Chien C.C., Liu J.W. Antimicrobial effects of varied combinations of meropenem, sulbactam, and colistin on a multidrug-resistant Acinetobacter baumannii isolate that caused meningitis and bacteremia. Microb. Drug Resist. 14, 233-237, 2008.
48. Rodríguez Guardado A., Blanco A., Asensi V., et al. Multidrug-resistant Acinetobacter meningitis in neurosurgical patients with intraventricular catheters: assessment of different treatments. J. Antimicrob. Chemother. 61, 908-913, 2008.
49. Hachimi A., Charra B., Benslama A., Motaouakkil S. Intrathecal use of amikacin and colistin. Ann. Fr. Anesth. Reanim. 27. 113-114, 2008.
50. Rodriguez C.H., Bombicino K., Granados G., Nas tro M., Vay C., Famiglietti A. Selection of colistin-resistant Acinetobacter baumannii isolates in postneurosurgical meningitis in an intensive care unit with high presence of heteroresistance to colistin. Diagn. Microbiol. Infect. Dis. 65, 188-191, 2009.
51. López-Alvarez B., Martín-Láez R., Fariñas M.C., Paternina-Vidal B., García-Palomo J.D., Vázquez-Barquero A. Multidrug-resistant Acinetobacter baumannii ventriculitis: successful treatment with intraventricular colistin. Acta Neurochir. (Wien). 51, 1465-1472, 2009.
52. Dalgic N., Ceylan Y., Sancar M. et al. Successful treatment of multidrug-resistant Acinetobacter baumannii ventriculitis with intravenous and intraventricular colistin. Ann. Trop. Paediatr. 29, 141-147, 2009.
53. Baiocchi M., Catena V., Zago S., Badolati L., Baccarin M. Intrathecal colistin for treatment of multidrug resistant (MDR) Pseudomonas aeruginosa after eurosurgical ventriculitis. Infez. Med. 18, 182-186, 2010.
54. De Pascale G., Pompucci A., Maviglia R., et al. Successful treatment of multidrug-resistant Acinetobacter baumannii ventriculitis with intrathecal and intravenous colistin. Minerva Anestesiol. 76, 957-960, 2010.
55. Khawcharoenporn T., Apisarnthanarak A., Mundy L.M. Intrathecal colistin for drug-resistant Acinetobacter baumannii central nervous system infection: a case series and systematic review. Clin. Microbiol. Infect. 16, 888-894, 2010.
56. Cascio A., Conti A., Sinardi L., et al. Post-neurosurgical multidrug-resistant Acinetobacter baumannii meningitis successfully treated with intrathecal colistin. A new case and a systematic review of the literature. Int. J. Infect. Dis. 14, e572-579, 2010.
57. Kim K., Kang H.S., Sohn C.H., Oh B.M. Cauda equina syndrome misdiagnosed as aggravated hydrocephalus: neurological complication of intrathecal colistin in post-surgical meningitis. Acta Neurochir. (Wien). 153, 425-427, 2011.
58. Ozdemir H., Tapisiz A., Ciftçi E., et al. Successful treatment of three children with post-neurosurgical multidrug-resistant Acinetobacter baumannii meningitis. Infection. 38, 241-244, 2010.
59. Razmkon A., Mehrafshan A., Bakhtazad A. Management of post-neurosurgical Acinetobacter infections: experiences obtained during an outbreak. Acta Neurochir. (Wien). 153, 435-436, 2011.
60. Patel J.A., Pacheco S.M., Postelnick M., Sutton S. Prolonged triple therapy for persistent multidrugresistant Acinetobacter baumannii ventriculitis. Am. J. Health Syst. Pharm. 68, 1527-1531, 2011.
61. Saleem A.F., Shah M.S., Shaikh A.S., Mir F., Zaidi A.K. Acinetobacter species meningitis in children: a case series from Karachi, Pakistan. J. Infect. Dev. Ctries. 5, 809-814, 2011.
62. Alaoui S.Y., Nejmi S.E., Chakir A.A., Hmamouchi B., Chlilek A. Intraventricular colistin use in neonatal meningitis caused by Acinetobacter baumanii. Ann. Fr. Anesth. Reanim. 30, 854-855, 2011.
63. Wang J.H., Lin P.C., Chou C.H., et al. Intraventricular antimicrobial therapy in postneurosurgical Gram-negative bacillary meningitis or ventriculitis: A hospital-based retrospective study. J. Microbiol. Immunol. Infect. 47, 204-210, 2014.
64. Karaiskos I., Galani L., Baziaka F., et al. Successful treatment of extensively drug-resistant Acinetobacter baumannii ventriculitis and meningitis with intraventricular colistin after application of a loading dose: a case series. Int. J. Antimicrob. Agents. 41, 480-483, 2013.
65. Tumbarello M., Viale P., Viscoli C., et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin. Infect. Dis. 55, 943-950, 2012.
66. Liang W., Liu X.F., Huang J., Zhu D.M., Li J., Zhang J. Activities of colistin- and minocycline-based combinations against extensive drug resistant Acinetobacter baumannii isolates from intensive care unit patients. BMC Infect. Dis. 27, 11, 109, 2011.
67. Tan T.Y., Lim T.P., Lee W.H., Sasikala S., Hsu L.Y., Kwa A.L. In vitro antibiotic synergy in extensively drug-resistant Acinetobacter baumannii: the effect of testing by time-kill, checkerboard, and Etest methods. Antimicrob. Agents Chemother. 55, 436-438, 2011.
68. Tascini C., Gemignani G., Ferranti S., et al. Microbiological activity and clinical efficacy of a colistin and rifampin combination in multidrug-resistant Pseudomonas aeruginosa infections. J. Chemother. 16, 282-287, 2004.
69. Tascini C., Tagliaferri E., Giani T., et al. Synergistic activity of colistin plus rifampin against colistin-resistant KPC-producing Klebsiella pneumoniae. Antimicrob. Agents Chemother. 57, 3990-3993, 2013.